News about 'tb alliance'

Last week we posted information about two special issues of Future Medicinal Chemistry focused on neglected diseases. Future Medicinal Chemistry (September 2011, Volume 3, Number 11) have a few articles on tuberculosis drug development: Diarylquinolines, synthesis pathways and quantitative...

Special Focus: Neglected Diseases [PART 1]. Future Medicinal Chemistry. August 2011, Volume 3, Number 10 ( free issue ) Special Focus: Neglected Diseases [PART 2]. Future Medicinal Chemistry. September 2011, Volume 3, Number 11 (not yet released) The August and September issues of Future Medicinal...

The first detailed study of the private tuberculosis (TB) drug market, published on May 4 th , in the PLoS ONE journal, finds that the market is surprisingly large, and has irregular practices that could be driving treatment failures and contributing to the emergence of multidrug-resistant TB (MDR-...

Today on World TB Day, the International Scientific Exchange Foundation of China (ISEFC) , announced the signing of a Memorandum of Understanding with the Global Alliance for TB Drug Development (TB Alliance) to establish the Global Health R&D Center of China (GHRC). This innovative center will...

Elkington PT, D’Armiento JM, Friedland JS. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci Transl Med. 2011 Feb 23;3(71):71ps6. In today’s article, Elkington, et al., would like to change how researchers view and define immunopathology in tuberculosis. The...

2010 Annual Meeting Following the guest speakers ( click here to view that recap ), several representatives from companies conducting clinical trials of TB drug candidates presented brief updates on progress made in the clinical development of their candidates. Click the presentation name to...

2010 Annual Meeting Co-chairs of WGND, Mel Spigelmen and Bill Bishai opened the annual meeting by welcoming the attendees and briefly reviewing the agenda for the meeting. There were several guest speakers that presented on various topics including the website, community engagement, open source...

SABC Story on NC001 The clinical trial of the first novel regimen was featured today on SABC TV in South Africa. This is the first clinical trial to test multiple new TB drugs in combination; the trial is known as New Combination 1 (NC001). The experimental regimen undergoing testing in this trial...

NC001 Today, the TB Alliance announced the first clinical trial to test multiple new TB drugs in combination; the trial is known as New Combination 1 (NC001).The experimental regimen undergoing testing in this trial consists of experimental TB drugs PA-824, Moxifloxacin, and Pyrazinamide, an...

Review of JACS Communication, “Catalytic Asymmetric Synthesis of R207910″ By Christopher Cooper, Director of Chemistry, TB Alliance Retrosynthetic Approach to TMC207 (click to view larger) The novel antitubercular agent TMC207 ( Tibotec , a Johnson & Johnson company) represents an impressive...

This article originally appeared on Citizen News Service. Click here to read the original post. by Shobha Shukla Open Forum 4 The Open Forum 4 on key issues in tuberculosis (TB) drug development is all set to begin in Addis Ababa, Ethiopia (18-19 August 2010). This Open Forum 4, will raise and...

TB Alliance and DNDi Enter into a Unique Collaboration New Potential TB Drugs to be Investigated Against Multiple Neglected Diseases A Unique Collaboration: TB Alliance and DND i Enter Cross-Disease License Agreement to Speed Development of Novel Therapies New York, United States and Geneva,...

Clinical Research Scientist for the TB Alliance This video was recorded on November 13, 2009 at Johns Hopkins University. Dr. Martino Laurenzi Dr. Laurenzi, an expert in clinical development and community health, is a Clinical Research Scientist at the TB Alliance, where his responsibilities...

A Satellite Session at the 2nd TB Conference June 3, 2010; 16:00 – 18:00 MR 11, ICC, Durban Community engagement in TB drug research is growing practice, made possible by the fact that several new drug candidates are entering clinical trials. This roundtable will provide a forum for dialogue...

Global tuberculosis drug development pipeline: the need and the reality by Zhenkun Ma, Christian Lienhardt, Helen McIlleron, Andrew J Nunn, Xiexiu Wang Today, The Lancet published a series of articles on tuberculosis, which highlights the continued devastating global impact of this disease, the...